Study #2023-0831
ALLIANCE A012103: Optimice-pcr: De-escalation of therapy in early-stage TNBC patients who achieve pcr after neoadjuvant chemotherapy with checkpoint inhibitor therapy
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab
Description
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Study phase:
Phase III
Physician name:
Clinton Yam
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-211-1427
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.